BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37947008)

  • 21. Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma.
    Fortin Ensign SP; Jenkins RB; Giannini C; Sarkaria JN; Galanis E; Kizilbash SH
    Neuro Oncol; 2023 Jan; 25(1):28-36. PubMed ID: 35973817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Qualitative and Quantitative Magnetic Resonance Imaging Phenotypes May Predict CDKN2A/B Homozygous Deletion Status in Isocitrate Dehydrogenase-Mutant Astrocytomas: A Multicenter Study.
    Park YW; Park KS; Park JE; Ahn SS; Park I; Kim HS; Chang JH; Lee SK; Kim SH
    Korean J Radiol; 2023 Feb; 24(2):133-144. PubMed ID: 36725354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Astrocytoma (CNS WHO grade 4), IDH-mutant with co-occurrence of BRAF p.V600E mutation, and homozygous loss of CDKN2A.
    Leske H; Blakstad H; Lund-Iversen M; Skovholt EK; Niehusmann P; Ramm-Pettersen JT; Skogen K; Kongelf G; Sprauten M; Magelssen H; Brandal P
    Neuropathology; 2023 Oct; 43(5):385-390. PubMed ID: 36754566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033.
    Kros JM; Rushing E; Uwimana AL; Hernández-Laín A; Michotte A; Al-Hussaini M; Bielle F; Mawrin C; Marucci G; Tesileanu CMS; Stupp R; Baumert B; van den Bent M; French PJ; Gorlia T
    Neuro Oncol; 2023 Aug; 25(8):1443-1449. PubMed ID: 36571817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations.
    Yang RR; Shi ZF; Zhang ZY; Chan AK; Aibaidula A; Wang WW; Kwan JSH; Poon WS; Chen H; Li WC; Chung NY; Punchhi G; Chu WC; Chan IS; Liu XZ; Mao Y; Li KK; Ng HK
    Brain Pathol; 2020 May; 30(3):541-553. PubMed ID: 31733156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utility of real-time polymerase chain reaction for the assessment of CDKN2A homozygous deletion in adult-type IDH-mutant astrocytoma.
    Shimizu Y; Suzuki M; Akiyama O; Ogino I; Matsushita Y; Satomi K; Yanagisawa S; Ohno M; Takahashi M; Miyakita Y; Narita Y; Ichimura K; Kondo A
    Brain Tumor Pathol; 2023 Apr; 40(2):93-100. PubMed ID: 36788155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CDKN2A/p16 in ependymomas.
    Bortolotto S; Chiadò-Piat L; Cavalla P; Bosone I; Mauro A; Schiffer D
    J Neurooncol; 2001 Aug; 54(1):9-13. PubMed ID: 11763427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spatial heterogeneity in DNA methylation and chromosomal alterations in diffuse gliomas and meningiomas.
    Ferreyra Vega S; Wenger A; Kling T; Olsson Bontell T; Jakola AS; Carén H
    Mod Pathol; 2022 Nov; 35(11):1551-1561. PubMed ID: 35701666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A clinicopathological analysis of supratentorial ependymoma, ZFTA fusion-positive: utility of immunohistochemical detection of CDKN2A alterations and characteristics of the immune microenvironment.
    Hashimoto N; Suzuki T; Ishizawa K; Nobusawa S; Yokoo H; Nishikawa R; Yasuda M; Sasaki A
    Brain Tumor Pathol; 2023 Jul; 40(3):163-175. PubMed ID: 37322295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel MRI-based deep learning networks combined with attention mechanism for predicting CDKN2A/B homozygous deletion status in IDH-mutant astrocytoma.
    Zhang L; Wang R; Gao J; Tang Y; Xu X; Kan Y; Cao X; Wen Z; Liu Z; Cui S; Li Y
    Eur Radiol; 2024 Jan; 34(1):391-399. PubMed ID: 37553486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-Grade Endometrial Stromal Sarcomas With YWHAE::NUTM2 Gene Fusion Exhibit Recurrent CDKN2A Alterations and Absence of p16 Staining is a Poor Prognostic Marker.
    Kommoss FKF; Mar LM; Howitt BE; Hanley K; Turashvilli G; Buslei R; Irving JA; Dickson BC; Koelsche C; Sinn HP; Schirmacher P; von Deimling A; Chiang S; McCluggage WG; Croce S; Stewart CJR; Lee CH
    Mod Pathol; 2023 Mar; 36(3):100044. PubMed ID: 36788095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CDKN2A/B deletions are strongly associated with meningioma progression: a meta-analysis of individual patient data.
    Wach J; Basaran AE; Arlt F; Vychopen M; Seidel C; Barrantes-Freer A; Müller W; Gaunitz F; Güresir E
    Acta Neuropathol Commun; 2023 Nov; 11(1):189. PubMed ID: 38017560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations.
    Nielsen GP; Burns KL; Rosenberg AE; Louis DN
    Am J Pathol; 1998 Jul; 153(1):159-63. PubMed ID: 9665476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The rate of homozygous CDKN2A/p16 deletions in glioma cell lines and in primary tumors.
    Hartmann C; Kluwe L; Lücke M; Westphal M
    Int J Oncol; 1999 Nov; 15(5):975-82. PubMed ID: 10536182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EZH2 expression in gliomas: Correlation with CDKN2A gene deletion/ p16 loss and MIB-1 proliferation index.
    Purkait S; Sharma V; Jha P; Sharma MC; Suri V; Suri A; Sharma BS; Sarkar C
    Neuropathology; 2015 Oct; 35(5):421-31. PubMed ID: 26096306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preoperative Discrimination of CDKN2A/B Homozygous Deletion Status in Isocitrate Dehydrogenase-Mutant Astrocytoma: A Deep Learning-Based Radiomics Model Using MRI.
    Gao J; Liu Z; Pan H; Cao X; Kan Y; Wen Z; Chen S; Wen M; Zhang L
    J Magn Reson Imaging; 2024 May; 59(5):1655-1664. PubMed ID: 37555723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas.
    Barrow J; Adamowicz-Brice M; Cartmill M; MacArthur D; Lowe J; Robson K; Brundler MA; Walker DA; Coyle B; Grundy R
    Neuro Oncol; 2011 Feb; 13(2):212-22. PubMed ID: 21138945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. P16 deletion and mutation analysis in human brain tumors.
    Barker FG; Chen P; Furman F; Aldape KD; Edwards MS; Israel MA
    J Neurooncol; 1997 Jan; 31(1-2):17-23. PubMed ID: 9049826
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MRI Phenotype of RELA-fused Pediatric Supratentorial Ependymoma.
    Nowak J; Jünger ST; Huflage H; Seidel C; Hohm A; Vandergrift LA; von Hoff K; Rutkowski S; Pietsch T; Warmuth-Metz M
    Clin Neuroradiol; 2019 Dec; 29(4):595-604. PubMed ID: 30027327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CDKN2A deletion in pediatric versus adult glioblastomas and predictive value of p16 immunohistochemistry.
    Purkait S; Jha P; Sharma MC; Suri V; Sharma M; Kale SS; Sarkar C
    Neuropathology; 2013 Aug; 33(4):405-12. PubMed ID: 23311918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.